- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06748157
심방세동을 위한 카테터 절제 후 심방빈맥부정맥을 약화시키기 위한 비침습적 정중신경 자극 (NEUROPULSE)
Determine the role of vagal/median nerve stimulation using the CardiaCare RR2 home care wearable neuromodulation system on suppressing atrial arrhythmias and related symptoms in patients who have undergone AF ablation. The study population will be comprised of adults (age ≥18 yrs.) who have undergone AF ablation for paroxysmal or persistent AF.
The study will assess the ability of neuromodulation, using the CardiaCare RR2 home care wearable, to suppress the following:
- early (0-2 months) post-ablation arrhythmias that occur in the immediate post-ablation time period
- AF/AT/AFL recurrences between months 2-6 post-ablation.This is a prospective, controlled, double-blind, randomized trial. The first 15 patients will not be randomized and will receive the active median/vagal stimulation only (open label).
The Study will be conducted in up to 1 clinical site in the United States. This study will have 1:1 randomization (active median/vagal stimulation vs sham). The study has been given NSR designation from FDA--NO IDE.
연구 개요
상세 설명
Study will include continuous ECG assessment at 2 (0 for the first 15 patients, open label), 6 and 22 weeks from enrollment for 2 weeks (for 4 weeks at the first measurement for the first 15 patients, open label) and at least daily single lead ECG assessments throughout the follow up period. The ECG's generated can be viewed by physicians only to assess the frequency of RR2 treatments and will not be used to alter any other aspects of standard of care, including medical management, which will continue according to standard of care throughout the study. Patients and investigators will be blinded during the trial. Patients with paroxysmal or persistent AF undergoing AF ablation will be recruited post ablation procedure during hospitalization. During screening/baseline visit, eligible patients will be randomized to either an active treatment or a sham group (1:1 accordingly). The first 15 eligible patients will not be randomized and will receive the active median/vagal stimulation only (open label).
Patients will receive training on the RR2 for home-care use, by study personnel either in person or via a video conference meeting. An instructional video will also be available for users. Patients will be ordered to measure at home, 2 min ECG measurements with the RR2 system, two times a day throughout the study and when feeling symptoms suspected related to AF (AF/AT/PAC).
In addition, Patients will be instructed to perform Neuromodulation sessions with the RR2 home care device. Once a day for the first 2 weeks followed by three times per week for the remaining duration of the study. Additional treatments, up to once daily, will be added during this period in case the patient feels symptom, verified on single lead ECG and site staff.
Treatments will be conducted for a period of 6 months. During the study, the patients will continue to take Standard of care medication. Medications will be recorded throughout the study.
Patient Diary will be dispensed and or APP diary questioners will be used by the subject in order to document symptoms suspected as related to arrhythmia events.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
New York
-
New York, New York, 미국, 10029
- Icahn School of Medicine at Mount Sinai
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria
- Men and women ages ≥18 years
- Patients planned to undergo or undergoing AF ablation for paroxysmal or persistent AF and able to be randomized within 48 hours of the ablation procedure.
- Ability and willingness to sign an informed consent form.
- Ability and willingness to use CardiaCare RR2 device, continuous ECG monitoring, and has an available SmartPhone.
Exclusion Criteria
- Rheumatic heart disease
- Extensive atrial disease (* some patients may be determined to be screen failures following the ablation procedure).
- Moderate to severe mitral stenosis or history of mitral valve replacement
- Pacemaker or CRTD or any implanted electrical stimulating device
- Unilateral or bilateral vagotomy
- Peripheral neuropathy affecting the tested upper extremity.
- Severe heart failure (New York Heart Association Class III or IV) within 90 days.
- Recent (within 90 days) stroke or transient ischemic attack.
- Recent (within 90 days) myocardial infarction.
- Pregnancy or breast feeding.
- Life expectancy <1 year for any medical condition
- Currently enrolled in another study that would interfere with this study
- Unsuitable for participating in the study according to attending physician
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Participants with CardiaCare RR2
Participants undergoing Neuromodulation Sessions (mNVS) and Active Median/Vagal Stimulation. Patients will receive training on the RR2 for home-care use, by study personnel either in person or via a video conference meeting. An instructional video will also be available for users. |
CardiaCare has developed a wrist band that delivers non-invasive neuromodulation to the median nerve to elicit a vagal response (Median-Vagus nerve stimulation-mVNS). The device is in the post-prototype development stage and is ready for human clinical trials. The CardiaCare RR2 device has already been approved by the IRB of the Chaim Sheba Medical Center, IL and the IL MOH (Ministry of Health) in an already completed pilot clinical trial for modulating AF. |
|
가짜 비교기: Participants with Sham Device
Sham device will be dispensed, which will create a sensation but not provide therapy |
Sham device will be dispensed, which will create a sensation but not provide therapy |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
AF/AFL occurrence
기간: at 2-months and 6-months post-ablation procedure
|
Burden of AF/AFL (defines as 30 seconds or longer) during the 2-months and 6-months period after ablation measured using ECG-patch monitoring and daily RR2 single lead ECG. |
at 2-months and 6-months post-ablation procedure
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
응급실 방문 횟수
기간: 절제 후 6개월
|
절제 후 6개월
|
|
|
입원 횟수
기간: 절제 후 6개월
|
절제 후 6개월
|
|
|
심장율동전환 횟수
기간: 절제 후 6개월
|
절제 후 6개월
|
|
|
절제 재실행 횟수
기간: 절제 후 6개월
|
절제 후 6개월
|
|
|
Time to first Atrial tachycardia (AT) or Atrial Fibrillation (AF) recurrence
기간: 2-month and 6-month post-ablation procedure
|
Time to first AT or AF recurrence measured by CardiaCare RR2 |
2-month and 6-month post-ablation procedure
|
|
Number of arrythmia occurrences
기간: 2-month and 6-month post-ablation procedure
|
Burden of all arrythmias between 2- and 6-months period after ablation will be measured using 2 weeks ECG-patch monitoring and daily RR2 single lead ECG. |
2-month and 6-month post-ablation procedure
|
|
Number of Atrial Arrythmia Symptoms
기간: 6-month post-ablation procedure
|
Difference in Atrial Arrythmia Symptoms during the 6 months period after ablation. |
6-month post-ablation procedure
|
|
Time to first Atrial tachycardia (AT) or Atrial Fibrillation (AF) recurrence
기간: 6 months post-ablation
|
Time to first Atrial tachycardia (AT) or Atrial Fibrillation (AF) recurrence during the 6-months period after ablation. |
6 months post-ablation
|
|
Quality of Life measured using The European Heart Rhythm Association (EHRA) score
기간: Baseline, 2-months, and 6-months
|
The investigators will assess the change in EHRA symptom scale. The EHRA score ranges from 1 to 4. Higher scores indicate more severe symptoms. |
Baseline, 2-months, and 6-months
|
|
Quality of Life measured using Atrial Fibrillation Effect on QualiTy-of-life (AFEQT) Score
기간: Baseline, 2-months, and 6-months
|
The AFEQT is a questionnaire assessing quality of life and symptoms in atrial fibrillation patients. It covers four subscales: patient symptoms, daily activities, treatment concerns, and treatment satisfaction. Subscales from 0-100, with Full Scale range from 0 to 100, with higher scores indicating better quality of life and fewer symptom burdens. |
Baseline, 2-months, and 6-months
|
|
Change in PAC/AT/AFL before and after treatment with RR2
기간: Baseline and 6-month post-ablation
|
Change, such as increase or decrease, in incidence/frequency of atrial arrhythmias before and after treatment with study device. |
Baseline and 6-month post-ablation
|
|
Change in Heart Rate Variability (HRV)
기간: Baseline and 6-month post-ablation
|
Heart rate variability (HRV) is the variation in the time interval between consecutive heartbeats. Higher HRV indicates better cardiovascular function and stress resilience. |
Baseline and 6-month post-ablation
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Vivek Reddy, MD, Icahn School of Medicine at Mount Sinai
- 수석 연구원: Mohit Turagam, MD, Icahn School of Medicine at MS
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .